Completed PHASE2 INTERVENTIONAL 4-arm NCT01074294

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder (STEP-A)

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adult Attention Deficit/ Hyperactivity Disorder

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions Attention Deficit Hyperactivity Disorder

Interventions OPDC-34712 Placebo Stimulant Therapy

Updated 8 times since 2017 Last updated: Jan 6, 2023 Started: Mar 16, 2010 Primary completion: Jun 20, 2011 Completion: Jun 20, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Attention Deficit Hyperactivity Disorder and is currently completed. Otsuka Pharmaceutical Development & Commercialization, Inc. leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2023 — Jul 2024 [monthly]

Completed PHASE2
Apr 2022 — Mar 2023 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Data source: Otsuka Pharmaceutical Development & Commercialization, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Austin, United States , Bellevue, United States , Beverly Hills, United States , Bradenton, United States , Chapel Hill, United States , Cherry Hill, United States , Cincinnati, United States , Dayton, United States , Durham, United States and 25 more locations